ReviewVirology journal2010
Selective gene silencing by viral delivery of short hairpin RNA.
Review in Virology journal, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 104 citations in OpenAlex.
- Translocating shRNA: a novel approach to RNA interference with Newcastle disease virus as viral vector.The Journal of general virology · 2025Article
- Non-coding RNAs in osteoarthritis and osteoporosis-related hip fractures: molecular biomarkers for precision diagnosis and prognosis.Frontiers in endocrinology · 2025Review
- microRNAs: Key Regulators in Plant Responses to Abiotic and Biotic Stresses via Endogenous and Cross-Kingdom Mechanisms.International journal of molecular sciences · 2024Review
- Identification of genes associated with gall bladder cell carcinogenesis: Implications in targeted therapy of gall bladder cancer.World journal of gastrointestinal oncology · 2023Review
- Polθ Inhibition: An Anticancer Therapy for HR-Deficient Tumours.International journal of molecular sciences · 2022Review
- Review
- Nanomedicine for the Delivery of RNA in Cancer.Cancers · 2022Review
- Recent trends in miRNA therapeutics and the application of plant miRNA for prevention and treatment of human diseases.Future journal of pharmaceutical sciences · 2022Review
- Targeting Inflammasome Activation in COVID-19: Delivery of RNA Interference-Based Therapeutic Molecules.Biomedicines · 2021Review
- Article
- Hepatitis B Virus-Like Particle: Targeted Delivery of Plasmid Expressing Short Hairpin RNA for Silencing theInternational journal of molecular sciences · 2021Article
- Next Generation dsRNA-Based Insect Control: Success So Far and Challenges.Frontiers in plant science · 2021Review
- Simultaneous downregulation of miR-21 and upregulation of miR-7 has anti-tumor efficacy.Scientific reports · 2020Article
- [Osteogenic effect of collagen/bioglass composites carrying noggin siRNA].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2018Article
- Engineered Flock House Virus for Targeted Gene Suppression Through RNAi in Fruit Flies (Frontiers in physiology · 2018Article
- Stable knockdown of CREB, HIF-1 and HIF-2 by replication-competent retroviruses abrogates the responses to hypoxia in hepatocellular carcinoma.Cancer gene therapy · 2017Article
- Cellular Delivery of RNA Nanoparticles.ACS combinatorial science · 2016Review
- Genetic screening reveals a link between Wnt signaling and antitubulin drugs.The pharmacogenomics journal · 2016Article
- Down-Regulation of Cytokinin Oxidase 2 Expression Increases Tiller Number and Improves Rice Yield.Rice (New York, N.Y.) · 2015Article
- Technologies for controlled, local delivery of siRNA.Journal of controlled release : official journal of the Controlled Release Society · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RNA interference (RNAi) technology has not only become a powerful tool for functional genomics, but also allows rapid drug target discovery and in vitro validation of these targets in cell culture. Furthermore, RNAi represents a promising novel therapeutic option for treating human diseases, in particular cancer. Selective gene silencing by RNAi can be achieved essentially by two nucleic acid based methods: i) cytoplasmic delivery of short double-stranded (ds) interfering RNA oligonucleotides (siRNA), where the gene silencing effect is only transient in nature, and possibly not suitable for all applications; or ii) nuclear delivery of gene expression cassettes that express short hairpin RNA (shRNA), which are processed like endogenous interfering RNA and lead to stable gene down-regulation. Both processes involve the use of nucleic acid based drugs, which are highly charged and do not cross cell membranes by free diffusion. Therefore, in vivo delivery of RNAi therapeutics must use technology that enables the RNAi therapeutic to traverse biological membrane barriers in vivo. Viruses and the vectors derived from them carry out precisely this task and have become a major delivery system for shRNA. Here, we summarize and compare different currently used viral delivery systems, give examples of in vivo applications, and indicate trends for new developments, such as replicating viruses for shRNA delivery to cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.